Corrigendum to “Heterologous Two-dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-lasting Cellular Immunity to Influenza Virus A in Healthy Adults” [EBioMedicine 29 (2018) 146–154] (S2352396418300653) (10.1016/j.ebiom.2018.02.011));Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults

EBioMedicine

Volumn 29, Issue , 2018, Pages 146-154

  Coughlan, L ^a   Sridhar, S ^f   Payne, R ^e   Edmans, M ^e   Milicic, A ^e   Venkatraman, N ^e   Lugonja, B ^e   Clifton, L ^b   Qi, C ^b   Folegatti, P M ^e   Lawrie, A M ^e   Roberts, R ^e   de Graaf, H ^c   Sukhtankar, P ^c   Faust, S N ^c   Lewis, D J M ^d   Lambe, T ^e   Hill, A V S ^e   Gilbert, S C ^e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY OF SURREY   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f SANOFI PASTEUR   (France)

Author keywords

Adults; Influenza; Influenza vaccines; Older adults; T cell responses; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; GAMMA INTERFERON; MATRIX PROTEIN; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; POXVIRUS VECTOR; VIRUS NUCLEOPROTEIN;

ADULT; APPLICATION SITE SWELLING; ARM PAIN; ARTHRALGIA; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEMALE; FEVER; FLOW CYTOMETRY; FOLLOW UP; HEADACHE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA A VIRUS; INJECTION SITE WARMTH; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; POXVIRIDAE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIMIAN VIRUS; SKIN REDNESS; T LYMPHOCYTE; VACCINATION;

EID: 85042870948     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2018.05.001     Document Type: Erratum

References (20)

1. Antrobus, R.D., Lillie, P.J., Berthoud, T.K., Spencer, A.J., Mclaren, J.E., Ladell, K., Lambe, T., Milicic, A., Price, D.A., Hill, A.V., Gilbert, S.C., A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years. PLoS One, 7, 2012, e48322.
2. Antrobus, R.D., Berthoud, T.K., Mullarkey, C.E., Hoschler, K., Coughlan, L., Zambon, M., Hill, A.V., Gilbert, S.C., Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses. Mol. Ther. 22 (2014), 233–238.
3. Antrobus, R.D., Coughlan, L., Berthoud, T.K., Dicks, M.D., Hill, A.V., Lambe, T., Gilbert, S.C., Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol. Ther. 22 (2014), 668–674.
4. Berthoud, T.K., Hamill, M., Lillie, P.J., Hwenda, L., Collins, K.A., Ewer, K.J., Milicic, A., Poyntz, H.C., Lambe, T., Fletcher, H.A., Hill, A.V., Gilbert, S.C., Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin. Infect. Dis. 52 (2011), 1–7.
5. Haq, K., Mcelhaney, J.E., Immunosenescence: influenza vaccination and the elderly. Curr. Opin. Immunol. 29 (2014), 38–42.
6. Hayward, A.C., Wang, L., Goonetilleke, N., Fragaszy, E.B., Bermingham, A., Copas, A., Dukes, O., Millett, E.R., Nazareth, I., Nguyen-Van-Tam, J.S., Watson, J.M., Zambon, M., Flu Watch, G., Johnson, A.M., Mcmichael, A.J., Natural T cell-mediated protection against seasonal and pandemic influenza. Results of the flu Watch cohort study. Am. J. Respir. Crit. Care Med. 191 (2015), 1422–1431.
7. He, X.S., Holmes, T.H., Zhang, C., Mahmood, K., Kemble, G.W., Lewis, D.B., Dekker, C.L., Greenberg, H.B., Arvin, A.M., Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J. Virol. 80 (2006), 11756–11766.
8. Heldens, J.G., Weststrate, M.W., Van den Hoven, R., Area under the curve calculations as a tool to compare the efficacy of equine influenza vaccines—a retrospective analysis of three independent field trials. J. Immunol. Methods 264 (2002), 11–17.
9. Hillaire, M.L., Van Trierum, S.E., Bodewes, R., Van Baalen, C.A., Van Binnendijk, R.S., Koopmans, M.P., Fouchier, R.A., Osterhaus, A.D., Rimmelzwaan, G.F., Characterization of the human CD8(+) T cell response following infection with 2009 pandemic influenza H1N1 virus. J. Virol. 85 (2011), 12057–12061.
10. Jefferson, T., Rivetti, D., Rivetti, A., Rudin, M., Di Pietrantonj, C., Demicheli, V., Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet 366 (2005), 1165–1174.
11. Lillie, P.J., Berthoud, T.K., Powell, T.J., Lambe, T., Mullarkey, C., Spencer, A.J., Hamill, M., Peng, Y., Blais, M.E., Duncan, C.J., Sheehy, S.H., Havelock, T., Faust, S.N., Williams, R.L., Gilbert, A., Oxford, J., Dong, T., Hill, A.V., Gilbert, S.C., Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin. Infect. Dis. 55 (2012), 19–25.
12. Mcelhaney, J.E., Kuchel, G.A., Zhou, X., Swain, S.L., Haynes, L., T-cell immunity to influenza in older adults: a pathophysiological framework for development of more effective vaccines. Front. Immunol., 7, 2016, 41.
13. Mcmichael, A.J., Gotch, F.M., Dongworth, D.W., Clark, A., Potter, C.W., Declining T-cell immunity to influenza, 1977-82. Lancet 2 (1983), 762–764.
14. Mcmichael, A.J., Gotch, F.M., Noble, G.R., Beare, P.A., Cytotoxic T-cell immunity to influenza. N. Engl. J. Med. 309 (1983), 13–17.
15. Pebody, R.G., Warburton, F., Ellis, J., Andrews, N., Thompson, C., VON Wissmann, B., Green, H.K., Cottrell, S., Johnston, J., DE Lusignan, S., Moore, C., Gunson, R., Robertson, C., Mcmenamin, J., Zambon, M., Low effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2014/15 mid-season results. Euro Surveill, 20, 2015, 21025.
16. Petrie, J.G., Cheng, C., Malosh, R.E., Vanwormer, J.J., Flannery, B., Zimmerman, R.K., Gaglani, M., Jackson, M.L., King, J.P., Nowalk, M.P., Benoit, J., Robertson, A., Thaker, S.N., Monto, A.S., Ohmit, S.E., Illness severity and work productivity loss among working adults with medically attended acute respiratory illnesses: US influenza vaccine effectiveness network 2012-2013. Clin. Infect. Dis. 62 (2015), 448–455.
17. Rivetti, D., Jefferson, T., Thomas, R., Rudin, M., Rivetti, A., Di Pietrantonj, C., Demicheli, V., Vaccines for preventing influenza in the elderly. Cochrane Database Syst. Rev., 19(3), 2006, CD004876.
18. Sridhar, S., Begom, S., Bermingham, A., Hoschler, K., Adamson, W., Carman, W., Bean, T., Barclay, W., Deeks, J.J., Lalvani, A., Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 19 (2013), 1305–1312.
19. Van de Sandt, C.E., Hillaire, M.L., Geelhoed-Mieras, M.M., Osterhaus, A.D., Fouchier, R.A., Rimmelzwaan, G.F., Human influenza a virus-specific CD8+ T-cell response is long-lived. J. Infect. Dis. 212 (2015), 81–85.
20. Wilkinson, T.M., Li, C.K., Chui, C.S., Huang, A.K., Perkins, M., Liebner, J.C., Lambkin-Williams, R., Gilbert, A., Oxford, J., Nicholas, B., Staples, K.J., Dong, T., Douek, D.C., Mcmichael, A.J., Xu, X.N., Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18 (2012), 274–280.